Wharton Alumni Angels will be inviting Life Sciences companies to pitch to WAA Members on Thursday, 17-Oct-2024 from 4pm - 6:00pm PT // 7pm - 9:00pm ET.
This event is open to Wharton Alumni Angels Members. Attendees are invited and encouraged to participate in the post pitch discussion following the last presentation.
Presenting companies are listed below. Click on their company logo to visit them on Dealum and learn more.
Zoom joining information will be sent upon registering for this event.
PROPOSED AGENDA:
4:05pm PT // 7:05pm ET | AGED Diagnostics |
4:30pm PT // 7:30pm ET | Integral Dental |
4:55pm PT // 7:55pm ET | RNA NanoBiotics |
5:20pm PT // 8:20pm ET | Aurenar |
5:40pm PT // 8:40pm ET | WAA Member and Guest Post Pitch discussion |
AGED is developing the first accurate blood test for fatty liver disease for early detection and intervention.
- PROBLEM: Liver disease is the fastest growing epidemic in developed nations, affecting 1 in 3 (or 100 million) Americans. The challenge - there are zero effective noninvasive diagnostic tools, and many are unaware until the disease has progressed to later stages; at which time, the only effective treatment is a liver transplant, when outcomes are poor.
- SOLUTION: AGED is developing the first accurate diagnostic tool that can differentiate benign from advanced liver disease through a simple, easy to deploy blood test. Our efforts will provide physicians a non-invasive and accurate tool to identify high risk patients, reduce the financial burden on health insurers and improve early detection and intervention.
- AGED-WAA_Pitch Overview_10-Oct-2024
- Aged Diagnostics_Convertible Note Term Sheet_Oct-2024
- Of Note:
- As of 10-Oct-2024, raised $1.9 million in this $2.5 million round
- The minimum investment amount is $100,000 (per group) - the max is $1,000,000.
- #1-aged-diagnostics on Slack
Aurenar is revolutionizing stroke patient care with an ear-worn neurostimulation device with clinical proof of therapy
⭐Sourced by James Carroll
- PROBLEM: Aurenar is addressing life-threatening and costly complications following stroke as patients “wait to survive” in ICUs for weeks to months. Patients suffer vasospasm, infection, and hydrocephalus, leading to costly long-term care. Costs exceed $5k per day and can avalanche beyond $200k. Hospitals lose money under the fixed-rate DRG reimbursement.
- SOLUTION: Our noninvasive single-use neurostimulation device, V-Link, is applied 2x/day in the ICU. V-Link solves specific challenges for use in the ICU (no wires, pre-programmed, disposable, no CAPEX). It works by activating a cutaneous branch of the vagus nerve in the ear. Our clinical study has demonstrated significant clinical and cost benefits.
-
Of Note:
- Currently pursuing a priced equity round
- The total Aurenar is raising is $4M for a $15M premoney valuation
- Minimum amount of investment is $500K. Max amount would be $2M.
- Aurenar Pitch Deck_01-Oct-2024
- #1-aurenar on Slack
We've developed the only peri-implant disease diagnostic test available to support dentists' improved patient outcomes.
- PROBLEM: The number one reason dental implants fail is due to infection in the surrounding tissue. Doctors do not have enough information about early stages of infection nor which pathogens are present to design effective care plans in many cases. This lack of information drives later stage interventions of these infections that are less effective.
- SOLUTION: Our test involves collecting a simple plaque sample. This sample is shipped to our lab where we extract the DNA and sequence it to understand the composition of the microbial community. We run this data through our proprietary algorithms to create a report for the doctor that will not only diagnose the disease state but also make recommendations.
- Integral Dental-WAA_2024SeedRound_Pitch Deck for 17-Oct-2024
- Of Note:
- Raising $2-$3M for seed round with an anticipated valuation of $10M-$12M
- The investment vehicle will be in a priced round and we will share the term-sheet once it is finalized
- $500K allocation reserved for Wharton Alumni Angels
- #1-integral-dental on Slack
RNA Nanobiotics has RNA Nanotechnology for Targeted Delivery of RNAi, Radioisotopes, and Chemotherapeutics for Oncology
⭐Sourced by James Carroll
- PROBLEM: Cancer is the most deadly disease in the developed world as one in three people develop cancer in their lifetime. The cure for cancer is like the Holy Grail since most of the existing treatments are not effective enough to provide full protection from the disease.
- SOLUTION: RNA Nanobiotics was established to spearhead the translation of RNA nanotechnology into an innovative delivery system able to improve the therapeutic outcome of patients with cancer. Our proprietary RNA Nanotechnology Platform allows for Targeted Delivery of RNAi, Radioisotopes and Chemotherapeutics for safe and effective cancer treatments.
- RNA NonoBiotics Pitch Deck
-
Of Note:
- SAFE
- $12MM pre money valuation
- 20% discount upon conversion
- #1-rna-nanobiotics on Slack
This is a video event.
Please register below in advance of this meeting.
----------
Wharton Alumni Angels is not a venture fund, an investment bank, a broker/dealer, investment clearing‐house, or an investment advisor. Wharton Alumni Angels is not registered with the U.S. Securities Exchange Commission or any other state’s or nation’s securities commission. For tax, compliance, reporting, legal or other requirements, it is highly recommended that members seek appropriate professional help. No representation or warranty is made as to the accuracy or completeness of the information provided by Wharton Alumni Angels or companies presenting investment opportunities. Wharton Alumni Angels presumes that any offering conducted by companies is a private placement and does not involve a public solicitation of investment.